EcoDrugPlus

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSMLUG00000015186
Gene Symbol: PSMD4
2 Cross references
274 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSMLUG00000007471
Gene Symbol: PSMC1
2 Cross references
203 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSMLUG00000016615
Gene Symbol: PSMC3
4 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSMLUG00000017606
Gene Symbol: PSMC4
4 Cross references
197 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSMLUG00000011699
Gene Symbol: PSMC5
2 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSMLUG00000009181
Gene Symbol: PSMC6
2 Cross references
234 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSMLUG00000005205
Gene Symbol: PSMD1
4 Cross references
210 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSMLUG00000003874
Gene Symbol: PSMD11
2 Cross references
285 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSMLUG00000013464
Gene Symbol: PSMD12
2 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSMLUG00000009962
Gene Symbol: PSMD13
2 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 14

Ensembl ID : ENSMLUG00000006001
Gene Symbol: PSMD14
2 Cross references
213 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 3

Ensembl ID : ENSMLUG00000003342
Gene Symbol: PSMD3
2 Cross references
212 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).